MétaCan
Menu
Back to cohort
Record W4280647474 · doi:10.1016/j.jval.2022.04.1729

Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools

2022· article· en· W4280647474 on OpenAlexaff
Francesco Cerisoli, Farzad Ali, Tamás Bereczky, Natacha Bolaños, Lars Bullinger, Sujith Dhanasiri, James J. Gallagher, Sonia García Pérez, Jan Geißler, Yann Guillevic, Kathryn Harrison, Anastasia Naoum, Carla Portulano, Ana Eugenia Rodríguez Vicente, Renate Schulze‐Rath, Gabriela Yumi Gómez, Guillermo Sanz, Jesús María Hernández‐Rivas

Bibliographic record

VenueValue in Health · 2022
Typearticle
Languageen
FieldEconomics, Econometrics and Finance
TopicEconomic and Financial Impacts of Cancer
Canadian institutionsPfizer (Canada)Impact
FundersInnovative Medicines InitiativeEuropean CommissionEuropean Federation of Pharmaceutical Industries and Associations
KeywordsOffensiveMedicineHarmony (color)Health careAllianceClinical trialFamily medicinePolitical scienceInternal medicineOperations researchEngineering

Abstract

fetched live from OpenAlex

OBJECTIVES: The Innovative Medicines Initiative-funded, multistakeholders project Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology (HARMONY) created a task force involving patient organizations, medical associations, pharmaceutical companies, and health technology assessment/regulator agencies' representatives to evaluate the suitability of previously established value frameworks (VFs) for assessing the clinical and societal impact of new interventions for hematologic malignancies (HMs). METHODS: Since the HARMONY stakeholders identified the inclusion of patients' points of view on evaluating VFs as a priority, surveys were conducted with the patient organizations active in HMs and part of the HARMONY network, together with key opinion leaders, pharmaceutical companies, and regulators, to establish which outcomes were important for each HM. Next, to evaluate VFs against the sources of information taken into account (randomized clinical trials, registries, real-world data), structured questionnaires were created and filled by HARMONY health professionals to specify preferred data sources per malignancy. Finally, a framework evaluation module was built to analyze existing clinical VFs (American Society of Clinical Oncology, European Society of Medical Oncology, Magnitude of Clinical Benefit Scale, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, Institute for Clinical and Economic Review, National Comprehensive Cancer Network Evidence Blocks, and patient-perspective VF). RESULTS: The comparative analysis describes challenges and opportunities for the use of each framework in the context of HMs and drafts possible lines of action for creating or integrating a more specific, patient-focused clinical VF for HMs. CONCLUSIONS: None of the frameworks meets the HARMONY goals for a tool that applies to HMs and assesses in a transparent, reproducible, and systematic way the therapeutic value of innovative health technologies versus available alternatives, taking a patient-centered approach and using real-world evidence.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.241
metaresearch head score (Gemma)0.236
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.241
Threshold uncertainty score0.936

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.2410.236
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.004
Bibliometrics0.0230.018
Science and technology studies0.0040.006
Scholarly communication0.0180.015
Open science0.0040.015
Research integrity0.0020.004
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.232
GPT teacher head0.374
Teacher spread0.142 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueValue in HealthSame topicEconomic and Financial Impacts of CancerFrench-language works237,207